Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differentiating benign and malignant solitary pulmonary nodules through exhaled breath analysis.

ERJ open research·2026
Same author

Staging of Lung Cancer: A Call for Developing Uniform and Universal Key Performance Indicators and Benchmarks to Elevate Clinical Standards.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Hypoxia induces alterations in the volatile signature of pleural mesothelioma cells.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Multi-omic screening for pleural mesothelioma in Asbestos-Exposed Populations: A literature review and Recommendations.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Design and rationale of the ZORALCS study: An implementation study of lung cancer screening by low-dose computed tomography coupled to a smoking cessation randomized controlled trial in the Flemish region.

Journal of medical screening·2025
Same author

Haptoglobin phenotype: A germline risk factor for malignant pleural mesothelioma? A case-control study.

Clinica chimica acta; international journal of clinical chemistry·2025

Related Experiment Video

Updated: Apr 15, 2026

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.3K

Radiotherapy for single station N2 NSCLC.

Jan P van Meerbeeck1

  • 1Thoracic Oncology-MOCA, University Hospital Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium.

Translational Lung Cancer Research
|March 26, 2015
PubMed
Summary

Clinical single station N2 involvement, a moderately identifiable prognostic factor, shows no clear benefit from postoperative radiotherapy. Definitive chemoradiation offers equivalent outcomes to induction therapy followed by resection in adequately staged patients.

Keywords:
N2Radiotherapylung cancerstage IIIA

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.2K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.9K

Related Experiment Videos

Last Updated: Apr 15, 2026

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.3K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.2K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.9K

Area of Science:

  • Thoracic oncology
  • Surgical oncology
  • Radiation oncology

Background:

  • Clinical single station N2 involvement is a prognostic factor in lung cancer.
  • Preoperative identification of single station N2 is challenging, even with thorough mediastinal staging.
  • Limited evidence exists regarding the predictive value of single station N2 for radical treatment outcomes or the benefit of postoperative radiotherapy.

Purpose of the Study:

  • To evaluate the prognostic significance of clinical single station N2 involvement.
  • To compare the outcomes of definitive chemoradiation versus induction therapy followed by resection in patients with single station N2 disease.

Main Methods:

  • Retrospective analysis of adequately staged patients with clinical single station N2 involvement.
  • Comparison of survival and treatment outcomes between different therapeutic strategies.

Main Results:

  • Clinical single station N2 involvement has moderate preoperative identifiability.
  • Definitive chemoradiation therapy demonstrated equivalent outcomes to induction therapy followed by resection.
  • Postoperative radiotherapy did not show a clear benefit for this patient group.

Conclusions:

  • Definitive chemoradiation is a viable and effective treatment strategy for adequately staged patients with clinical single station N2 lung cancer.
  • The prognostic value of single station N2 in predicting treatment response requires further investigation.
  • Treatment decisions for single station N2 disease should consider modern chemoradiation approaches.